News | November 25, 2023
DxVx plans to make a license-in agreement of OVM-200
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
The products will be manufactured at the company's facility in Bengaluru
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
Subscribe To Our Newsletter & Stay Updated
